Register for Event

If your company is based in Massachusetts, consider applying for the Express Program grant at least 21 days before the course start date. If approved, the Express Program will either partially or fully cover the cost of your training after course completion based on your company size. Read more about the program here.

Member Rate applies for MassBio Member Company, Other State Bioscience Association Member Company, MassCONNECT Company, or Unemployed Individual

By registering for this course, you are eligible to receive a 10% discount applied to your registration of Business of Biotech 201. Contact to obtain the coupon code to enter when checking out.


Business of Biotech 101 explores the business considerations that drive company strategies. Students will be provided with foundational information about the BioPharma industry and regulation via instruction, storytelling, and breakout group discussions. Industry ethics will be discussed, with emphasis on historical precedents. The course touches on topics such as market share, phases of development, patient population, and safety profile. A high-level overview of Research and Development, including pre-clinical through market approval will also reviewed.


  1. Monday, September 13th, 2021 12:30-3:00 PM EST
  2. Tuesday, September 14th, 2021 12:30-3:00 PM EST
  3. Thursday, September 16th, 2021 12:30-3:00 PM EST


Session 1:
Origins of the Biotech Industry: a Brief History
Addressing Unmet Medical Need
Biotechnology techniques used for therapeutics development
Biotech Entrepreneurship
Business Models of the Sector and Industries within

Session 2:
Clinical Development
Creating Barriers to Entry: Market Exclusivity

Session 3
Early Stage Financing


John Tagliamonte
Chief Executive Officer, Mellitus

John Tagliamonte has more than 30 years of experience in executive leadership with responsibility for business development, finance, commercial and business operations, strategic planning, finance and legal functions with established and emerging public and private life sciences companies.  As the first Entrepreneur-in-Residence with MassBio, he was responsible for forward-looking program content across the organization, while helping to develop the next generation of biotech entrepreneurs. He currently serves on the business advisory boards of therapeutic startups WntRx, Fractal, MarkTx, PhagePro and Tantu.  Previously he led business development at Juniper, was Chief Business Officer of Oxyrane and held various executive business leadership roles at Anchor Therapeutics, ImmunoGen and Johnson & Johnson, as well as venture investing with Safeguard.  He began his career as a scientist at Dana-Farber Cancer Institute followed by global business unit management at Bio-Rad.  Mr. Tagliamonte received his M.B.A. from Boston College and his B.S. in molecular biology from Tufts University.

Atul Deshpande, Ph.D., MBA
Chief Executive Officer, IMMEDIATE Therapeutics

Atul is the CEO of IMMEDIATE Therapeutics, a clinical stage biotech company dedicated to developing safe and effective therapeutic solutions to reduce heart muscle damage and prevent cardiac arrest in Acute Coronary Syndromes (ACS), the most common cause of death and morbidity across the world.

Before joining IMMEDIATE Therapeutics, Atul was the Chief Strategy Officer and Head, US Operations of Harbour BioMed (HBM). Atul was primarily responsible for building the company’s short- and long-term strategy and portfolio along with a robust execution plan. In addition, he is also accountable for the HBM’s operations in both the US and EU to maintain HBM’s footprint across these 2 very important markets, along with managing key alliances in these regions. In 2020, he contributed to raising 2 VC funding rounds and taking the company public in the HK stock exchange raising a total of $400M.

Before HBM, Atul served as the Global Operations Head for the Dupixent Franchise with Sanofi. He led the operations, including marketing, market access, supply chain, to launch Dupixent in 52 markets across the world for Atopic Dermatitis and in major markets for Asthma. Prior to this, he led the operations for Sanofi’s Immunology R&D portfolio and was also responsible for new product planning and in-licensing evaluations. He spent 3 years in China as the Head of Asia Pacific R&D strategy to bring the global portfolio to China with minimal drug lag. Before Sanofi, Atul worked as a management consultant for 9 years on projects across the value chain of pharma. 

Atul holds a Ph.D. from UC Irvine in Neuroscience and a post-doc from UCLA.